A tacrolimus drug-eluting stent manufacturing method according to the present invention enables a tacrolimus drug to be strongly and stably bound onto a stent, while also not necessarily involving a separate step of introducing a surface-binding functional group for the binding of a drug onto a stent and a step of introducing, into the drug, a functional group capable of binding to the surface-binding functional group, and a tacrolimus drug-eluting stent manufactured by the manufacturing method has a greater total drug elution amount and has a more excellent delayed drug-elution property.

Various embodiments are described herein for an ocular device implantable in a user's eye and which has an adjustable optical element for varying one or more optical properties for the eye such as, but not limited to, providing a dynamically adjustable aperture stop to control the amount of incoming light, filtering incoming light, polarizing incoming light, and/or varying a depth of field for the eye.

A combination bioactive silicate (e.g., bioactive glass) medicine carrier and shunt of one embodiment includes a shunt which is a tubular member made of bioactive silicate or glass being adapted to be bioresorbable and water soluble, or fiber bundle, the shunt including an insertion end at a first end. Gaps in the bioactive silicate or gaps in the glass adapted to be bioresorbable and water soluble are served as at least one storage for storing medicines.

An intraocular drug delivery platform for use with an intraocular lens assembly. The platform includes a ring and haptics to maintain the ring in position in the capsular bag, compartments on the anterior surface of the ring for accommodating a drug eluting matrix or other drug mass, and a skirt extending posteriorly from the posterior surface of the ring to constrain movement, including lateral or inferior/superior movement, of the intraocular lens relative to the ring.

Disclosed herein is a medical device for extended release of drugs. The device is a self-retaining implantable drug delivery device embedded with one or more drug depots that release of a therapeutic agent in a controlled manner. Each end of the self-retaining implantable drug delivery device may contain one or more anchors or attachment points which enable self-retention of the medical device once properly placed. The device can also comprise one or more drug depots with a swellable or non-swellable anchor. The disclosed devices further comprises a biosensor to monitor physiological characteristics like, e.g., intraocular pressure (IOP).

A degradation data generator is used with a scaffold for delivery within a patient. The degradation data generator includes a driving circuit electrically coupled to drive an impedance of the scaffold. A detection circuit generates degradation data based on the impedance of the scaffold or other properties such as RF or lightwave transmission, conductance or absorption. The degradation data indicates an amount of biodegradation of the scaffold. A wireless transmitter is coupled to transmit the degradation data to a wireless degradation data receiver, while the scaffold is within the patient.

A prosthetic capsular device configured to be inserted in an eye includes a housing structure and a ring structure. The housing structure includes a first side, a second side opposite the first side, a third side, a fourth side opposite the third side, a posterior side including a refractive surface, an anterior side opposite the posterior side, and a longitudinal axis. The first side, the second side, the third side, the fourth side, the posterior side, and the anterior side at least partially define a cavity configured to contain an intraocular device (e.g., an IOL). The anterior side includes an opening. The ring structure includes a ring structure portion extending radially outward from proximate one of an end of the first side and an end of the second side.

The invention relates to an artificial eye lens comprising an optical part, which has a first optical side as viewed in a direction of an optical principal axis of the artificial eye lens and an opposite second optical side, wherein a structure with at least one depression is formed in a haptic arrangement of the artificial eye lens and/or in a surround that surrounds the optical part at least in certain areas and that differs from the haptic arrangement, wherein the structure is formed as a micro-perforation with a multiplicity of perforation zones and at least some perforation zones are filled at least in certain areas with at least one medicament for the purposes of producing a medicament repository. The invention also relates to a method for producing such an artificial eye lens.

Described herein are methods and devices for delivering a drug to the frontal sinus system. An inflatable implant is positioned within the frontal sinus system using an anchoring means secured within the frontal sinus cavity. A drug-containing fluid is released directly into the frontal sinus drainage system.

A drug-loaded implanted medical device and a preparation method therefor. The drug-loaded implanted medical device comprises a device body and grooves (2) distributed on the surface of the device body, and at least one of the grooves (2) is loaded with a solid drug (11); the solid drug (11) is a crystal or has a form in which a crystal coexists with an amorphous body. The preparation method is implemented by loading the solid drug (11) into at least one of the grooves (2) by means of solution crystallization.